Bioyas Biology: 2025 Net Profit of 113 Million Yuan, Focused on Core Blood Product Business

LightningPacketLoss · 2026-03-21T07:50:07+00:00

Boya Biology's 2025 annual report shows operating revenue of 2.06 billion yuan, an increase of 18.7% year-over-year; net profit of 113 million yuan, a decrease of 71.6% year-over-year; and a loss of 7.76 million yuan. The company will shift its focus to blood products, successfully transferred 80% of its equity stake to concentrate on core business, and is promoting the construction of intelligent factories to improve production efficiency and product quality.

LightningPacketLoss

2026-03-21 07:50:07

Abstract generation in progress

Recently, Boya Biological announced its 2025 annual report, stating that the company’s operating revenue was 2.06 billion yuan, an increase of 18.7% year-on-year; net profit attributable to shareholders was 113 million yuan, a decrease of 71.6%; non-recurring net profit loss was 7.76 million yuan, a decrease of 102.6%; net operating cash flow was 61.16 million yuan, a decrease of 79.6%; EPS (fully diluted) was 0.2235 yuan.

In its 2025 annual report, the company mentioned significant changes in its business operations. First, the company continues to pursue its strategic vision of “becoming a world-class blood product enterprise,” actively advancing its blood product business, and gradually divesting non-blood product businesses. The main products in the blood product segment include human serum albumin, immunoglobulins, and clotting factors.

During the reporting period, China Resources Boya Biological successfully transferred its holdings in Boya Xin and 80% of its shares to focus on its core blood product business. Meanwhile, the company is actively promoting the construction of smart factories to improve production efficiency and quality management, ensuring stable product pass rates and yield rates. Overall, the company has actively explored business focus and strategic adjustments during the reporting period, aiming to enhance core competitiveness and market position.

(Boya Biological Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes